EUVIMEDOtkrijte EUVIMED
Übersichtsarbeit

Recent advances in CD5+ diffuse large B-cell lymphoma

Ningning Yue, Qiqi Jin, Cuicui Li, Litian Zhang, Jiajia Cao, Chongyang Wu

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05974-8 ↗

At a glance

Übersichtsarbeit in Annals of Hematology, 2024. Written by Ningning Yue and 5 co-authors. Institution: Department of Hematology, Lanzhou University Second Hospital, Lanzhou, Gansu, 730030, China. Major MEDLINE topics: Lymphoma, Large B-Cell, Diffuse, CD5 Antigens, Antineoplastic Combined Chemotherapy Protocols, Doxorubicin. Cited 5 times so far (Crossref); 95 references. Funded by: National Natural Science Foundation of China, Scientific Research Project of Gansu Province, The "CuiYing postgraduate tutor" training program of Lanzhou University Second Hospital.

SažetakSubjectsBibliografski podaciCiteRelated studies

Abstract (original language)

Diffuse large B-cell lymphoma (DLBCL), the most common non-Hodgkin's lymphoma (NHL), is substantially heterogeneous. Approximately 5-10% of DLBCLs express CD5, which makes CD5+ DLBCL a rare subgroup. Different studies have shown that CD5+ DLBCL patients are often older and female and have higher lactate dehydrogenase levels, an Eastern Cooperative Oncology Group (ECOG) performance status > 1, and higher International Prognostic Index (IPI) scores. Moreover, patients often have advanced stage disease with a high incidence of central nervous system (CNS) relapse and bone marrow involvement. CD5+ DLBCL cells are more likely to express MYC, BCL-2, and MUM-1, less likely to express CD10, and most belong to the activated B-cell-like (ABC) subtype. The potential mechanisms underlying the poor prognosis of CD5+ DLBCL patients may be related to CD5-mediated B-cell receptor (BCR)-dependent and -independent pathways. The efficacy of the traditional rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen is unsatisfactory in CD5+ DLBCL patients. Despite supporting evidence from retrospective studies, it is currently unclear whether dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus rituximab (DA-EPOCH-R) can improve outcomes in this population. Several new drugs, such as Bruton tyrosine kinase inhibitors (BTKi), BCL-2 inhibitors, and CXCR4 antagonists, as well as immunotherapy, may help to improve the prognosis of CD5+ DLBCL patients, but additional clinical explorations are needed to determine the optimal therapeutic strategy for this disease.

Subjects

MeSH terms (MEDLINE)

Lymphoma, Large B-Cell, DiffuseCD5 AntigensAntineoplastic Combined Chemotherapy ProtocolsDoxorubicinHumansCyclophosphamideRituximabVincristinePrednisoneFemaleEtoposideMalePrognosis

Author keywords

CD5+ DLBCLHigh CNS relapseNovel therapyPoor prognosis

Substances

CD5 AntigensDoxorubicinCyclophosphamideRituximabVincristinePrednisoneEtoposideR-CHOP protocol

Authors and institutions

  • Department of Hematology, Lanzhou University Second Hospital, Lanzhou, Gansu, 730030, China.
  • Department of Hematology, Lanzhou University Second Hospital, Lanzhou, Gansu, 730030, China. wuchy0909@163.com.

Funding

  • National Natural Science Foundation of China
  • Scientific Research Project of Gansu Province
  • The "CuiYing postgraduate tutor" training program of Lanzhou University Second Hospital
  • The “CuiYing postgraduate tutor” training program of Lanzhou University Second Hospital

Cite

APA

Yue, N., Jin, Q., Li, C., Zhang, L., Cao, J., & Wu, C. (2024). Recent advances in CD5+ diffuse large B-cell lymphoma. Annals of Hematology. https://doi.org/10.1007/s00277-024-05974-8

Vancouver

Yue N, Jin Q, Li C, Zhang L, Cao J, Wu C. Recent advances in CD5+ diffuse large B-cell lymphoma. Annals of Hematology. 2024. doi:10.1007/s00277-024-05974-8

BibTeX
@article{Yue2024,
  author = {Yue, Ningning and Jin, Qiqi and Li, Cuicui and Zhang, Litian and Cao, Jiajia and Wu, Chongyang},
  title = {Recent advances in CD5+ diffuse large B-cell lymphoma},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05974-8}
}
Start for free →